The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5,850.00
Bid: 5,845.00
Ask: 5,850.00
Change: 65.00 (1.12%)
Spread: 5.00 (0.086%)
Open: 5,805.00
High: 5,860.00
Low: 5,785.00
Prev. Close: 5,785.00
DCC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DCC significantly expands in medical devices

8 Sep 2022 07:00

RNS Number : 6897Y
DCC PLC
08 September 2022
 

    

8 September 2022

 

 

DCC Healthcare significantly expands in medical devices with its largest acquisition to date

Scale platform in European medical devices sector

 

DCC plc, the leading international sales, marketing, and support services group, announces that DCC Healthcare has agreed to acquire Medi-Globe Technologies GmbH ("Medi-Globe"), an international medical devices business focused on minimally invasive procedures. The transaction represents DCC Healthcare's largest acquisition to date and is a further material expansion of DCC Vital's presence in the European healthcare market, following on from the acquisition of primary care supplier Wörner Medical in May 2021.

 

The acquisition is based on an enterprise value of approximately €245 million (£213 million) on a cash-free, debt-free basis and the consideration will be settled in cash on completion. The acquisition is expected to generate a mid-teen return on capital employed in three years. The transaction is subject to competition authority approval in Germany and France and is expected to complete in calendar Q4 2022.

 

Medi-Globe, founded in 1990, is involved in the development, manufacture and distribution of single-use devices for endoscopy in diagnostic and therapeutic procedures. The business has grown organically and through bolt-on acquisitions to become a leading global player in its focus areas of gastroenterology and urology. These are large and growing therapeutic areas, benefiting from strong demographic and treatment trends. Medi-Globe has revenues of approximately €120 million (£104 million) and employs approximately 600 people. Its products are sold to hospitals and procurement organisations in over 120 countries through direct sales operations in Germany, France, Austria, Netherlands, Czechia and Brazil; and an international network of distributors. The business has significant regulatory and R&D capability with a strong development pipeline of innovative proprietary products. Medi-Globe sources its products from high quality manufacturers, as well as its own cleanroom facility in Czechia. Its highly experienced management team will continue to lead the business from its headquarters in Bavaria, Germany.

 

DCC Vital's growth strategy is principally focused on building its international presence in own-brand medical devices and in primary care supplies and services. DCC Vital's existing own-brand medical devices activities are focused on the areas of minimally invasive surgery, cardiac monitoring and anaesthesia. The addition of Medi-Globe creates an international platform of scale in single-use devices with high-quality product development, regulatory and manufacturing capability; direct sales and marketing infrastructure in eight countries and an extensive international distributor network. The acquisition will provide meaningful synergy opportunities, in particular through leveraging DCC Vital and Medi-Globe's respective product portfolios and commercial infrastructures.

 

 

Donal Murphy, Chief Executive of DCC plc, said today:

 

"We are delighted to welcome Medi-Globe into the DCC Group. The synergistic acquisition of Medi-Globe significantly expands and enhances DCC Vital's position in the medical devices sector. It will create a leading international platform in single-use medical devices for minimally invasive procedures, with strong product development capability.

 

The acquisition of Medi-Globe and other recent acquisitions in DCC Healthcare and DCC Technology are consistent with our ambition to really scale our operations in these higher growth sectors. We are very pleased with DCC Vital's progress in expanding its market positions beyond Britain and Ireland - we now have strong European growth platforms in both medical devices and primary care supplies."

  

Presentation - audio webcast and conference call details:

DCC will host an audio webcast and conference call for analysts and institutional investors at 09:00 BST today, 8 September 2022. The slides for this presentation can be downloaded from DCC's website: www.dcc.ie. The access details for the presentation are as follows:

 

Ireland: +353 (0) 1 536 9584

UK: +44 (0) 2039 362 999

International: +44 (0) 2039 362 999

Passcode: 981365

 

Webcast Link: https://www.investis-live.com/dcc/62d564d4d943801400a29223/ddcc

 

A replay of the webcast and transcript will be made available at www.dcc.ie shortly after the event.

 

 

Contact information

 

Investor enquiries:

Kevin Lucey, Chief Financial Officer Tel: +353 1 2799 400

Hollie Daly, Investor Relations Manager Email: investorrelations@dcc.ie

Media enquiries:

Powerscourt (Eavan Gannon/Genevieve Ryan) Tel: +44 20 7250 1446

Email: DCC@powerscourt‐group.com

 

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on sustainable growth. DCC is an ambitious and entrepreneurial business operating in 21 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

 

Headquartered in Dublin, the Group operates across three sectors: energy, healthcare and technology, employing over 15,400 people. DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2022, DCC generated revenue of £17.7 billion and adjusted operating profit of £589.2 million.

 

DCC has an excellent record, delivering compound annual growth of 14% in adjusted operating profit and generating an average return on capital employed of approximately 19% over 28 years as a public company.

 

Follow us on LinkedIn, Twitter.

www.dcc.ie

 

 

About DCC Healthcare

DCC Healthcare is a leading healthcare business providing products and services to health & beauty brand owners and healthcare providers. DCC Healthcare has revenues of over £765 million and circa 2,800 employees across its operations in Britain, Ireland, USA and the DACh region. DCC Healthcare has two areas of activity:

· DCC Vital: sales, marketing and distribution of medical products to healthcare providers across all sectors of the healthcare market in the UK, Ireland and DACh from hospitals through to community care and primary care.

· DCC Health & Beauty Solutions: provision of outsourced services to international Health & Beauty brand owners principally in the Nutrition and Beauty sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUBSRRUWUKRUR
Date   Source Headline
29th Nov 20191:39 pmRNSTotal Voting Rights
27th Nov 20199:18 amRNSDirector Declaration
18th Nov 20196:14 pmRNSDirector/PDMR Shareholding
12th Nov 20197:00 amRNSResults for the six months ended 30 September 2019
12th Nov 20197:00 amRNSDCC Healthcare acquires Ion Laboratories
7th Nov 201911:30 amRNSHolding in Company TR-1
23rd Oct 20192:25 pmRNSHolding in Company TR-1
21st Oct 20195:01 pmRNSHolding in Company TR-1
18th Oct 20194:46 pmRNSHolding in Company TR-1
17th Oct 20199:43 amRNSHolding in Company TR-1
25th Sep 20195:39 pmRNSHolding in Company TR-1
4th Sep 20199:57 amRNSHolding in Company TR-1
9th Aug 201910:42 amRNSHolding in Company TR-1
7th Aug 20199:23 amRNSHolding in Company TR-1
31st Jul 20192:58 pmRNSTotal Voting Rights
16th Jul 20196:14 pmRNSDirector/PDMR Shareholding
12th Jul 20193:06 pmRNSResult of AGM
12th Jul 20197:00 amRNSInterim Management Statement
5th Jul 20199:06 amRNSHolding in Company TR-1
19th Jun 20199:22 amRNSHolding in Company TR-1
13th Jun 201911:37 amRNS2019 Annual Report, Notice of AGM and Proxy Form
31st May 20199:47 amRNSTotal Voting Rights
28th May 20197:00 amRNSHolding in Company TR-1
23rd May 20196:25 pmRNSDirector/PDMR Shareholding
22nd May 20199:43 amRNSHolding in Company TR-1
16th May 20199:03 amRNSHolding in Company TR-1
14th May 20197:01 amRNSDCC Development Update
14th May 20197:00 amRNSResults for the year ended 31 March 2019
13th May 201910:14 amRNSBoard Change
28th Mar 20198:47 amRNSDirector Declaration
28th Feb 20199:00 amRNSTotal Voting Rights
5th Feb 20197:00 amRNSInterim Management Statement
1st Feb 20194:25 pmRNSHolding in Company TR-1
25th Jan 20193:12 pmRNSHolding in Company TR-1
22nd Jan 20192:27 pmRNSHolding in Company TR-1
10th Jan 201912:58 pmRNSHolding in Company TR-1
2nd Jan 20193:07 pmRNSHolding in Company TR-1
14th Dec 201811:50 amRNSHolding in Company TR-1
12th Dec 20189:08 amRNSHolding in Company TR-1
30th Nov 20183:03 pmRNSTotal Voting Rights
29th Nov 20184:50 pmRNSHolding in Company TR-1
19th Nov 20186:01 pmRNSHolding in Company TR-1
19th Nov 20185:59 pmRNSDirector/PDMR Shareholding
19th Nov 20182:27 pmRNSDirector/PDMR Shareholding
13th Nov 20187:00 amRNSResults for the six months ended 30 September 2018
6th Nov 20185:45 pmRNSHolding in Company TR-1
31st Oct 20183:26 pmRNSTotal Voting Rights
30th Oct 20189:51 amRNSBoard Resignation
24th Oct 20185:58 pmRNSHolding in Company TR-1
2nd Oct 20185:37 pmRNSHolding in Company TR-1

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.